Normal view

Received — 26 March 2026 ⏭ Nature Cancer

Nature Cancer
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results Rashmi K. Murthy · Barbara J. O’Brien · Donald A. Berry · Akshara Singareeka-Raghavendra · Maria Gule Monroe · Jason Johnson · Jason White · Jill Schwartz-Gomez · Ariel Topletz-Erickson · Mina Lobbous · Kristen Riley · Michelle Melisko · Aki Morikawa · Sherise D. Ferguson · John F. de Groot · Ian E. Krop · Vicente Valero · Mothaffar F. Rimawi · Antonio C. Wolff · Debu Tripathy · Nancy U. Lin · Erica M. Stringer-Reasor
Nature Cancer, Published online: 18 March 2026; doi:10.1038/s43018-026-01120-7Murthy and colleagues discussed recent research on the effect of a tucanitib–trastuzumab–capecitabine regimen in patients with HER2+ breast cancer and leptomeningeal metastasis.
18 March 2026 at 08:00

Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results

18 March 2026 at 08:00

Nature Cancer, Published online: 18 March 2026; doi:10.1038/s43018-026-01120-7

Murthy and colleagues discussed recent research on the effect of a tucanitib–trastuzumab–capecitabine regimen in patients with HER2+ breast cancer and leptomeningeal metastasis.